Please ensure Javascript is enabled for purposes of website accessibility
Accessibility Menu
MacroGenics Stock Quote

MacroGenics (NASDAQ: MGNX)

$16.07
(-0.2%)
-$0.03
Price as of April 18, 2024, 4:00 p.m. ET

MacroGenics Return vs. S&P

1 Year 5 Year 5 Year Annualized Since IPO
MGNX +135.29% -0.86% -0.17% -36%
S&P +20.62% +72.50% +11.51% +196%

MacroGenics Company Info

MacroGenics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of antibody-based therapeutics for the treatment of cancer. Its product pipeline includes Margetuximab, Flotetuzumab, Retifanlimab, Enoblituzumab, Tebotelimab, MGC018, MGD019, IMGC936, and MGD014 for infectious diseases. The company was founded by Scott E. Koenig, Jeffrey V. Ravetch, LeRoy E. Hood, Ruedi Aebersold, and Alan Aderem on August 14, 2000 and is headquartered in Rockville, MD.

News & Analysis

Valuation

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.